- Home
- XIFR vs NTLA Comparison
XIFR vs NTLA Comparison
Compare XIFR & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XIFR
- NTLA
- Stock Information
- Founded
- XIFR 2014
- NTLA 2014
- Country
- XIFR United States
- NTLA United States
- Employees
- XIFR N/A
- NTLA N/A
- Industry
- XIFR
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- XIFR
- NTLA Health Care
- Exchange
- XIFR NYSE
- NTLA Nasdaq
- Market Cap
- XIFR 874.5M
- NTLA 710.1M
- IPO Year
- XIFR N/A
- NTLA 2016
- Fundamental
- Price
- XIFR $8.82
- NTLA $6.87
- Analyst Decision
- XIFR Sell
- NTLA Buy
- Analyst Count
- XIFR 3
- NTLA 20
- Target Price
- XIFR $9.00
- NTLA $38.40
- AVG Volume (30 Days)
- XIFR 1.2M
- NTLA 4.8M
- Earning Date
- XIFR 05-08-2025
- NTLA 05-08-2025
- Dividend Yield
- XIFR 20.67%
- NTLA N/A
- EPS Growth
- XIFR N/A
- NTLA N/A
- EPS
- XIFR N/A
- NTLA N/A
- Revenue
- XIFR $1,255,000,000.00
- NTLA $45,569,000.00
- Revenue This Year
- XIFR $11.22
- NTLA N/A
- Revenue Next Year
- XIFR $1.90
- NTLA N/A
- P/E Ratio
- XIFR N/A
- NTLA N/A
- Revenue Growth
- XIFR 15.14
- NTLA N/A
- 52 Week Low
- XIFR $7.53
- NTLA $5.90
- 52 Week High
- XIFR $34.45
- NTLA $28.18
- Technical
- Relative Strength Index (RSI)
- XIFR N/A
- NTLA 38.33
- Support Level
- XIFR N/A
- NTLA $8.93
- Resistance Level
- XIFR N/A
- NTLA $9.79
- Average True Range (ATR)
- XIFR 0.00
- NTLA 0.58
- MACD
- XIFR 0.00
- NTLA -0.15
- Stochastic Oscillator
- XIFR 0.00
- NTLA 1.35
About XIFR XPLR INFRASTRUCTURE LP
NextEra Energy Partners LP is formed to acquire, manage, and own contracted clean energy projects. It owns interests in wind and solar projects in North America, as well as natural gas infrastructure assets in Texas. Renewable energy assets consist of wind, solar, and solar-plus-storage projects and a stand-alone battery storage project, as well as contracted natural gas pipeline assets. Renewable energy sales generate maximum revenue for the company.
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.